If you experience side effects, its okay to stay at your current dose
Most patients see net blood pressure reduction over time, but the trajectory is less predictable
The GLP-1 agonist slowing gastric emptying can affect the glucose peak from meals, which in turn affects insulin timing
The C20 fatty di-acid moiety, attached at Lys-20 via a Glu2AEEA linker, enables reversible albumin binding and is structurally analogous to, but longer than, the C18 chain used in semaglutide
Studies have shown that patients on these medications, combined with lifestyle changes, can achieve substantial weight loss, often in the range of 15% to over 20% of their total body weight, making them a powerful tool in the fight against obesity
However, a few states already offer at least some coverage for semaglutide for weight loss